Julie K Jadlowsky
Overview
Explore the profile of Julie K Jadlowsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1069
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jadlowsky J, Hexner E, Marshall A, Grupp S, Frey N, Riley J, et al.
Nat Med
. 2025 Jan;
PMID: 39833408
Long-term risks of gene therapy are not fully understood. In this study, we evaluated safety outcomes in 783 patients over more than 2,200 total patient-years of observation from 38 T...
2.
Dimitri A, Baxter A, Chen G, Hopkins C, Rouin G, Huang H, et al.
Sci Adv
. 2024 Nov;
10(46):eadp9371.
PMID: 39536093
CD8 T cell exhaustion hampers control of cancer and chronic infections and limits chimeric antigen receptor (CAR) T cell efficacy. Targeting in CAR T cells provides therapeutic benefit; however, TET2's...
3.
Klapwijk J, Del Rio Espinola A, Libertini S, Collin P, Fellows M, Jobling S, et al.
Hum Gene Ther
. 2024 Jul;
35(15-16):527-542.
PMID: 39049734
Regulators and industry are actively seeking improvements and alternatives to current models and approaches to evaluate potential carcinogenicity of gene therapies (GTs). A meeting of invited experts was organized by...
4.
Jadlowsky J, Chang J, Spencer D, Warrington J, Levine B, June C, et al.
Cancer Immunol Res
. 2024 Jul;
12(9):1132-1135.
PMID: 39018097
Methods to engineer the genomes of human cells for therapeutic intervention continue to advance at a remarkable pace. Chimeric antigen receptor-engineered T lymphocytes have pioneered the way for these therapies,...
5.
Chang J, Wellhausen N, Engel N, Landmann J, Hopkins C, Salas-Mckee J, et al.
Cancer Immunol Res
. 2024 Jun;
12(9):1136-1146.
PMID: 38869428
Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T...
6.
Tebas P, Jadlowsky J, Shaw P, Tian L, Esparza E, Brennan A, et al.
J Clin Invest
. 2024 May;
134(9).
PMID: 38690741
No abstract available.
7.
Bagley S, Logun M, Fraietta J, Wang X, Desai A, Bagley L, et al.
Nat Med
. 2024 Mar;
30(5):1320-1329.
PMID: 38480922
Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in...
8.
Jadlowsky J, Leskowitz R, McKenna S, Karar J, Ma Y, Dai A, et al.
Mol Ther Methods Clin Dev
. 2024 Jan;
32(1):101186.
PMID: 38282894
The use of lentiviral vectors in cell and gene therapy is steadily increasing, both in commercial and investigational therapies. Although existing data increasingly support the usefulness and safety of clinical-grade...
9.
Jung I, Noguera-Ortega E, Bartoszek R, Collins S, Williams E, Davis M, et al.
Cell Rep Med
. 2023 May;
4(6):101053.
PMID: 37224816
Chimeric antigen receptor (CAR) T cells demonstrate remarkable success in treating hematological malignancies, but their effectiveness in non-hematopoietic cancers remains limited. This study proposes enhancing CAR T cell function and...
10.
Jung I, Narayan V, McDonald S, Rech A, Bartoszek R, Hong G, et al.
Sci Transl Med
. 2022 Nov;
14(670):eabn7336.
PMID: 36350986
Chimeric antigen receptor (CAR) T cells have not induced meaningful clinical responses in solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during prolonged tumor antigen exposure...